May 13 2020
Two studies were published recently weighting in on the association of ACE-2 inhibitors (Angiotensin Converting Enzyme Inhibitors), ARBs (Angiotensin Receptor Blockers) and viral infections.
A group of cardiologists from continental Europe looked into SARS-CoV-2 virus, its tropism to angiotensin-converting enzyme 2 receptors, and cardiovascular mortality.
The study compared 2,022 patients with heart failure and 1,698 in validation cohort.
The bottom line:
The study does not support previous reports suggesting that ACE inhibitors or ARBs increase the vulnerability for COVID-19 through increased plasma ACE2 concentrations;
A group of cardiologists from the United Kingdom looked Into association between angiotensin blockade and the incidence of influenza.
The bottom line:
The use of ACE inhibitors and ARBs was associated with either no effect on the incidence of influenza or a lower incidence, depending on the duration of use. These associations regarding observed susceptibility to influenza may reflect mechanisms that are shared with coronaviruses, including SARS-CoV-2.
Dr. Why bottom line:
SARS-CoV-2 and Influenza affect angiotensin system in a similar manner, e.g. “novel” SARS-Cov-2 is old news;
ACE inhibitors and ARBs are associated with lower incidence of influenza and are not associated with higher risk of cardiovascular events in COVID-19;
We shall consider small doses of ACE inhibitors and ARBs for chemoprophylaxis of these infections;
Under no circumstances STOP your medications.
Surprise, surprise! Dr. Why was right!
See Dr. Why blogs:
Apr 23 If You Speak The Truth...
Apr 22 The Study Of 5700 Patients
Mar 30 Do Not Stop ACE-inhibitors or ARBs!
Mar 30 Am I on an ACE Inhibitor?
Feb 25 There is nothing you can do other than to maintain excellent general health